STOCKHOLM, Aug. 25, 2020 /PRNewswire/ -- IRRAS AB, a
commercial-stage medical technology company with a comprehensive
portfolio of innovative products for neurocritical care, today
announced the issuance of U.S. Patent No. 10,687,720 B2 for
"Automatic Air Management System."
"The air management system that is protected by this newest
patent drives the innovation that Hummingbird brings to the ICP
monitoring space," added Will
Martin, President and Chief Commercial Officer of
IRRAS. "Hummingbird uses this air system to calculate a
patient's intracranial pressure and provides the most accurate ICP
measurement of any commercially available system. We look
forward to expanding our US launch of the product family throughout
the remainder of 2020 and are working towards an EU launch.
"The patent covers claims involving an automatic air management
system that is used to measure intracranial pressure (ICP) via an
air pressure catheter that is placed within a patient. The
patent, which provides protection until 2035, is part of a family
of patents and patent applications protecting the core mechanism of
action of the Hummingbird ICP Monitoring System. This product
family includes the Hummingbird Quad, the only multi-lumen access
bolt that combines ventricular drainage, parenchymal ICP, and sites
for the placement of two additional probes, and Hummingbird Solo,
the most accurate and easiest to use parenchymal ICP monitor for
which IRRAS recently announced the first successful patient
treatment.
"We are pleased to strengthen our intellectual property
portfolio with the addition of our sixth U.S. patent for
Hummingbird," said Adam Sampson,
Vice President Product Excellence of IRRAS. "When combined
with the robust patents for our IRRAflow system, this patent
bolsters and expands protection of IRRAS' product portfolio, the
most innovative in neurocritical care."
About IRRAS
IRRAS is a global medical care company focused on delivering
innovative medical solutions to improve the lives of critically ill
patients. IRRAS designs, develops, and commercializes neurocritical
care products that transform patient outcomes and decrease the
overall cost of care by addressing complications associated with
current treatment methodologies. IRRAS markets and sells its
comprehensive, innovative IRRAflow and Hummingbird ICP
Monitoring product lines to hospitals worldwide through its direct
sales organization in the United
States and select European countries as well as an
international network of distribution partners.
IRRAS maintains its headquarters in Stockholm, Sweden, with corporate offices in
Munich, Germany, and San Diego, California, USA. For more
information, please visit www.irras.com.
IRRAS is listed on Nasdaq Stockholm (ticker: IRRAS).
For more information, please contact:
USA
Kleanthis G. Xanthopoulos,
Ph.D.
CEO
ir@irras.com
Europe
Sabina Berlin
CFO
+46 73 951 95 02
sabina.berlin@irras.com
The information was released for public disclosure, through
the agency of the contact person above, on August 25, 2020 at 10:00 (CET).
This information was brought to you by Cision
http://news.cision.com
https://news.cision.com/irras/r/irras-granted-sixth-patent-for-hummingbird-icp-monitoring-product-line-from-united-states-patent-and,c3179156